Funding for this research was provided by:
Merck Sharp and Dohme S.A
Conselleria d'Educació, Investigació, Cultura i Esport (Prometeo 2017/0173, Prometeo 2017/0173)
Received: 28 December 2019
Accepted: 20 January 2021
First Online: 5 February 2021
Ethics approval and consent to participate
: Ethics Committee of Clinical research at the San Juan of Alicante University General Hospital (18/303 on 5 February 2018).
: Not applicable.
: The design, planning and execution of the study and the analysis and interpretation of the results corresponded to the authors. Paloma Fernández and Isabel Hurtado of Merck Sharp & Dohme of Spain S.A. coordinated the presentation of the study to the Spanish Rare Diseases Federation [Federación Española de Enfermedades Raras] (FEDER) Board of Directors and were responsible for coordinating the study with this federation. They did not participate in the design of the study, nor in the analysis and interpretation of the results. IEXPAC is an instrument co-participated by Miguel Hernández University of Elche, BIOEF (Fundación Vasca de Investigación e Innovación Sanitarias), Institut Catalá de la Salut (ICS) and Merck Sharp & Dohme de España S.A.